Communiqués Gilead Sciences, Inc. Buenos Aires S.E.

Actions

GILD

ARBCOM4601C4

Produits pharmaceutiques

Cours en clôture Buenos Aires S.E. 14/08/2026			Varia. 5j.	Varia. 1 janv.
54 375,00 ^ARS	-0,55%		+3,47%	+16,04%

11/08	Les géants mondiaux de la pharmacie investissent des milliards pour renforcer leur présence aux États-Unis	RE
11/08	Nucleai et Gilead Sciences font progresser l'intelligence tissulaire par IA grâce à une collaboration d'envergure sur les ADC en oncologie	CI

Communiqués

07/08	Gilead Sciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
05/08	Gilead Sciences : Second Quarter 2026 Summary of Remarks	PU
04/08	Gilead: Q2 Earnings Snapshot	AQ
04/08	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results	BU
03/08	Gilead Sciences : Statement on California Supreme Court Decision in TDF Litigation	PU
29/07	South Africa's Next HIV Battle Isn't About Science, It's About Access	AQ
24/07	CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer	BU
24/07	AIDS 2026 - Gilead, Governments Must Make HIV Prevention Medicine More Accessible	AQ
23/07	Positive Interim Findings On New Once-Weekly HIV Treatment Pill	AQ
21/07	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026	BU
21/07	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure	BU
02/07	Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease	PU
24/06	U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer	BU
23/06	European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors	BU
16/06	U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	AQ
15/06	U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention	BU
12/06	Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief	BU
11/06	National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership	BU
09/06	UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir	AQ
05/06	Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa	BU
02/06	Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)	BU
27/05	Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)	BU
22/05	FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)	BU
22/05	Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors	BU
21/05	New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology	BU